Evidence map›Paper›PMID 35876950›Full record

ArticleJournal of cancer research and clinical oncology2023

The role of microRNA-30c in targeting interleukin 6, as an inflammatory cytokine, in the mesenchymal stem cell: a therapeutic approach in colorectal cancer.

Mohamad Mahjoor, Hamed Afkhami, Mohammad Najafi, Atieh Nasr, Samaneh Khorrami

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 32 citations in OpenAlex.

  1. Observational
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Mohamad MahjoorDepartment of Immunology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Hamed AfkhamiDepartment of Medical Microbiology, Faculty of Medicine, Shahed University of Medical Sciences, Tehran, Iran.
Mohammad NajafiDepartment of Biochemistry, Faculty of Medical, Iran University of Medical Sciences, Tehran, Iran.
Atieh NasrDepartment of Biochemistry, Islamic Azad University of Najafabad, Esfahan, Iran.
Samaneh KhorramiDepartment of Immunology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran. khorami.s@iums.ac.ir.
Iran University of Medical Sciences · IRIslamic Azad University of Najafabad · IRShahed University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionColorectal cancer (CRC) is the third most prevalent cancer and the second significant cause of cancer-associated death worldwide. The microRNA-30 is a substantial member of the miRNA family and plays a vital role in expanding several cancers. This microRNA potentially targets interleukin 6 as an inflammatory cytokine in CRC. MATERIALS AND

methodsMSCs were isolated and identified from mice bone marrow and then transduced with lentiviruses containing miR-30C. Transfected MSCs were collected to evaluate IL-6 levels, CT-26 cells were also co-cultured with MSCs, and the effect of apoptosis and IL-6 on the supernatant was assessed.

resultsOur result showed the expression of IL-6 mRNA and the level of protein were decreased in the supernatant of miR-30-transduced MSC cells compared to the control group. In addition, the rate of apoptosis was assessed, and the obtained data revealed the induction of apoptosis in CT-26 cells when they are in the vicinity of miR-30c-transduced MSCs. DISCUSSION AND

conclusionWe demonstrated that downregulation of miR-30c was significantly correlated with CRC progression and survival. So, the present study elucidated the anticancer effects of miR-30c in CRC and presented a novel target for CRC therapy.

Indexed as

Colorectal NeoplasmsMesenchymal Stem CellsMicroRNAsAnimalsCell ProliferationCytokinesInterleukin-6MiceCytokinesInterleukin-6interleukin-6, mouseMicroRNAsAnticancerColorectal cancerInterleukin 6Mesenchymal stem cellsMicroRNA-30

Identifiers

PMID35876950
PMCPMC11797002
OpenAlexW4287307290

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.